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Abstract
Directed differentiation of human pluripotent stem cells into func-
tional insulin-producing beta-like cells holds great promise for cell
replacement therapy for patients suffering from diabetes. This
approach also offers the unique opportunity to study otherwise
inaccessible aspects of human beta cell development and function
in vitro. Here, we show that current pancreatic progenitor differ-
entiation protocols promote precocious endocrine commitment,
ultimately resulting in the generation of non-functional polyhor-
monal cells. Omission of commonly used BMP inhibitors during
pancreatic specification prevents precocious endocrine formation
while treatment with retinoic acid followed by combined EGF/KGF
efficiently generates both PDX1+ and subsequent PDX1+/NKX6.1+
pancreatic progenitor populations, respectively. Precise temporal
activation of endocrine differentiation in PDX1+/NKX6.1+ progeni-
tors produces glucose-responsive beta-like cells in vitro that
exhibit key features of bona fide human beta cells, remain func-
tional after short-term transplantation, and reduce blood glucose
levels in diabetic mice. Thus, our simplified and scalable system
accurately recapitulates key steps of human pancreas develop-
ment and provides a fast and reproducible supply of functional
human beta-like cells.
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Introduction
Diabetes mellitus type 1 and 2 (T1D, T2D) are diseases characterized
by autoimmune destruction or progressive dysfunction and subse-
quent loss of insulin-producing pancreatic beta cells, respectively.
Current treatments for both types of patients with diabetes consist of
regulating blood glucose levels through injections of exogenous
insulin. While this approach provides reasonable management of
the diseases, unwanted risks and long-term complications persist
due to the inability of tightly maintaining glucose levels within a
normal physiological range. Complications include life-threatening
episodes of hypoglycemia, as well as long-term complications from
hyperglycemia resulting in micro- and macro-angiopathy leading to
cardiovascular pathologies and kidney failure, as well as neuropa-
thy. Thus, there is a need for distinct treatments that provide supe-
rior control of glucose metabolism to minimize or ideally eliminate
long-term complications.
One existing approach to treating diabetes is transplantation of
human cadaveric islet preparations into patients. This procedure
typically results in better glycemic control, can render patients insu-
lin independent for prolonged periods of time, and improves overall
quality of life (Shapiro et al, 2000; Posselt et al, 2010; Barton et al,
2012). However, the severe shortage of cadaveric organ donors,
requirement for lifelong immunosuppression, and variability
between islet preparations hampers the use of islet transplantation
as a readily available treatment for people with diabetes. Conse-
quently, numerous research efforts have focused on identifying
abundant alternative sources of surrogate glucose-responsive insu-
lin-producing cells (Zhou & Melton, 2008; Tudurı´ & Kieffer, 2011;
Efrat & Russ, 2012; Hebrok, 2012; Nostro & Keller, 2012; Bouwens
et al, 2013; Pagliuca & Melton, 2013). One of the most appealing
approaches is the directed differentiation into insulin-producing
cells from pluripotent human embryonic stem cells (hESCs)
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(D’Amour et al, 2005; Chen et al, 2009; Mfopou et al, 2010; Nostro
et al, 2011; Van Hoof et al, 2011; Xu et al, 2011; Guo et al, 2013b;
Shim et al, 2014) and, more recently, induced pluripotent stem cells
(Maehr et al, 2009; Hua et al, 2013; Shang et al, 2014).
Comprehensive knowledge of signaling events and temporal
transcription factor (TF) expression patterns during rodent pancreas
organogenesis (Hebrok, 2003; Murtaugh & Melton, 2003; Pan &
Wright, 2011; Seymour & Sander, 2011) have accelerated the identi-
fication of culture conditions that allow the generation of pancreatic
cell types from human pluripotent stem cells (hPSCs). Early devel-
opmental stages, including definitive endoderm, gut tube-like cells,
and pancreatic progenitors can be efficiently induced in vitro.
However, subsequent transitions toward hormone-expressing cells
in vitro are less efficient and frequently lead to the formation of a
mixed population of different pancreatic progenitors and polyhor-
monal endocrine cells (D’Amour et al, 2006; Nostro et al, 2011;
Guo et al, 2013a). Such polyhormonal cells express insulin among
other hormones, but lack expression of key beta cell transcription
factors and do not secrete insulin in vitro in response to a glucose
challenge—the hallmark function of bona fide beta cells (D’Amour
et al, 2006; Nostro et al, 2011; Guo et al, 2013a). Nonetheless,
transplantation of such heterogeneous cultures into surrogate mice
results in the formation of glucose-responsive beta-like cells after
several months in vivo (Kroon et al, 2008; Rezania et al, 2012; Szot
et al, 2015). Sophisticated sorting experiments identified progenitor
cells expressing pancreatic and duodenal homeobox 1 TF (PDX1,
also known as IPF1) and homeobox protein NKX6.1 as the source
for these functional beta-like cells (Kelly et al, 2011). While poly-
hormonal cells have been identified in human fetal pancreas,
suggesting that they may reflect aspects of the normal embryonic
differentiation process (De Krijger et al, 1992; Riedel et al, 2011),
increasing evidence indicates that hESC-derived polyhormonal cells
preferentially give rise to single-hormone-positive alpha-like cells
(Rezania et al, 2011). Thus, to fully replicate human beta cell devel-
opment in vitro, it is imperative to better understand and accurately
recapitulate the sequence of embryonic signals required for the
proper specification of beta cell precursors, rather than alpha cell
precursors.
During normal in vivo pancreatic organogenesis, functional beta
cells are generated through a stepwise specification process start-
ing with pancreatic progenitors, identified by the expression of
Pdx1 (Herrera et al, 2002). While Pdx1+ cells can give rise to all
pancreatic lineages (Herrera et al, 2002), the subsequent induction
of Nkx6.1 in these cells restricts their differentiation potential to
only endocrine and ductal cells (Schaffer et al, 2010). Endocrine
differentiation is then initiated in Pdx1+/Nkx6.1+ progenitors by
short-lived expression of the basic helix loop helix TF neurogenin
3 (Neurog3, also known as Ngn3) (Gu et al, 2002). Interestingly,
the timing of Neurog3 expression has been shown to be crucial
in promoting the formation of diverse endocrine islet cell types
(Johansson et al, 2007). For example, precocious induction of
endocrine differentiation by forced expression of Neurog3 in mice
results predominantly in the generation of alpha cells
(Johansson et al, 2007). Given that hESC-derived polyhormonal
cells have been shown to give rise to alpha cells (Rezania et al,
2011), we hypothesized that the in vitro generation of poly-
hormonal endocrine cells results from premature assignment to
the endocrine fate.
To address this issue, we performed a detailed stepwise analysis
of pancreatic progenitor generation and endocrine induction. Most
current protocols efficiently establish PDX1+ progenitors by using
retinoic acid in combination with molecules to inhibit bone morpho-
genic protein (BMP) and sonic hedgehog (SHH) signaling pathways,
while simultaneously adding either fibroblast growth factor 10 or
keratinocyte growth factor (KGF, also known as FGF7) (Mfopou
et al, 2010; Nostro & Keller, 2012; Rezania et al, 2012; Guo et al,
2013b; Hua et al, 2013). Here, we show that the use of BMP inhibi-
tors to specify pancreatic cells promotes the precocious induction of
endocrine differentiation in PDX1+ pancreatic progenitors, which
results in the formation of polyhormonal cells. Furthermore, we
have identified simplified culture conditions that replicate fetal
endocrine development and allow for the precise and efficient
generation of PDX1+ and PDX1+/NKX6.1+ progenitor populations
without precocious activation of the endocrine marker NEUROG3.
Importantly, subsequent induction of endocrine differentiation in
correctly specified PDX1+/NKX6.1+ progenitor cells results in the
formation of glucose-responsive insulin-expressing beta-like cells
in vitro within less than 3 weeks. Our study therefore details a
simplified directed differentiation protocol that closely recapitulates
key aspects of human endocrine development and results in the
formation of large numbers of glucose-responsive beta-like cells
under cell culture conditions.
Results
Pancreatic differentiation of hESCs using a large-scale culture
system results in two distinct subsets of insulin-producing cells
To generate pancreatic beta-like cells from human PSC, we estab-
lished a scalable three-dimensional suspension culture system based
on previously reported methods (Rezania et al, 2012; Schulz et al,
2012) (Fig 1A). To monitor the generation of live insulin-producing
cells and facilitate their isolation, we employed the recently
published INSGFP/W reporter cell line (Micallef et al, 2012) in which
green fluorescence protein (GFP) expression is under the control of
the endogenous insulin promoter. Using this differentiation proto-
col, GFP reporter expression was readily observed at day 13 and
increased thereafter, resulting in an average of 37  8% GFP+ cells
between days 19 and 24 (Fig 1B–D). The validity of GFP as an accu-
rate substitute for insulin was verified by staining with an insulin
specific antibody, which revealed an even higher percentage of insu-
lin-producing cells (up to 60%) likely due to delayed accumulation
of the fluorescence marker (Fig 1E). Similar results were obtained
with an antibody specific to human C-peptide, excluding antibody
reactivity due to insulin uptake from culture media (Fig 1E).
Co-staining for human C-peptide and glucagon (GCG), a hormone
normally produced by alpha cells, showed that 4.3% and 13.2% of
all cells exhibited a polyhormonal phenotype at day 13 and day 19,
respectively (Fig 1F). Co-staining for C-peptide and NKX6.1 at day
20 indicated the presence of some double-positive beta-like cells
(Fig 1G). Quantitative flow cytometry analysis revealed that the
proportion of insulin and NKX6.1 double-positive beta-like cells
increased from less than 2.5% at day 13 to approximately 12% cells
at day 19 of total cells (Fig 1G). Ultrastructural analysis of differenti-
ated cultures showed cells containing secretory vesicles with an
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electron-dense core surrounded by an electron-light halo (Fig 1H), a
morphology reminiscent of insulin vesicles that are found in human
beta cells. However, the majority of cells exhibited a mixture of
secretory granules usually found in non-beta cells of human
pancreas preparations (Fig 1H). Thus, differentiation experiments
employing published protocols (Rezania et al, 2012; Schulz et al,
A
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Figure 1. Pancreatic differentiation of hESCs using a large-scale culture system results in two distinct subsets of insulin-producing cells.
A Schematic outlining the differentiation protocol employed. R, retinoic acid; C, cyclopamine; N, Noggin, E, epidermal growth factor; K, keratinocyte growth factor; T,
TBP; A, ALK inhibitor.
B Micrograph of MEL1INS-GFP cell clusters after 17 days of differentiation demonstrating strong GFP expression (GFP expression in white). Scale bar, 200 lm.
C Flow cytometric analysis at day 20 of differentiation showing 41.5% of all cells expressing GFP under the control of the endogenous insulin promoter.
D Quantification by flow cytometry of the average percentage of GFP+ cells within differentiated cultures after 19–24 days. n = 7. Values are average  standard
deviation (SD).
E Flow cytometric analysis of intracellular human-specific C-peptide (C-PEP) and insulin (INS) shows comparable percentages of C-PEP and INS+ cells.
F Immunofluorescence staining for C-PEP and glucagon (GCG), and flow cytometric quantification of GCG+/C-PEP+ (red gate) and GCG/C-PEP+ (black gate) populations
at days 13 and 19 of differentiation.
G Immunofluorescence staining for C-PEP and NKX6.1, and flow cytometric quantification of NKX6.1+/INS+ (green gate) and NKX6.1/INS+ (red gate) populations at day
13 and 19. Immunofluorescence insets show two distinct phenotypes for C-PEP+ cells (NKX6.1+ and NKX6.1). A robust INS/NKX6.1 double-positive population is only
detected at day 19.
H Transmission electron microscopy of day 20 clusters. Cells contain both secretory vesicles with electron-dense cores surrounded by electron-light halos (green box),
akin to bona fide beta cell vesicles, as well as other granules similar to those found in non-beta pancreatic cells (red boxes).
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2012) result in the efficient generation of two distinct insulin-
producing cell populations: INS+ cells that do not co-express the
critical TF NKX6.1 and manifest as polyhormonal cells, and INS+/
NKX6.1+ beta-like cells that more closely resemble human beta
cells. Notably, INS+/NKX6.1+ beta-like cells are absent from
cultures at earlier time points but appear and increase in number at
later stages of differentiation, suggesting that they are derived from
a distinct progenitor cell type.
Defining the temporal activities of individual signaling factors to
efficiently generate PDX1+ and PDX1+/NKX6.1+ pancreas
progenitor populations while preventing precocious induction of
endocrine differentiation
To characterize the type of progenitors present in differentiating
cultures at the point of endocrine induction, we performed a
detailed time-course analysis for the expression of pancreatic mark-
ers PDX1, NKX6.1, NEUROG3, GCG, and INS (Supplementary Fig
S1). High expression of the progenitor marker PDX1 was efficiently
induced and maintained starting 1 day after the combined addition
of retinoic acid (R), the SHH inhibitor cyclopamine (C), and the
BMP inhibitor Noggin (N) to the culture media (referred to as RCN,
day 6, Supplementary Fig S1A and B). Subsequent treatment with
epidermal growth factor (EGF), KGF, and N (EKN) resulted in the
robust generation of PDX1+/NKX6.1+ double-positive cells, reach-
ing 67% of the total population at day 11 (Supplementary Fig S1A
and B). Immunofluorescence analysis revealed that the RCN cocktail
of factors widely used to generate pancreatic endoderm also induces
precocious expression of NEUROG3 in PDX1+ pancreatic progeni-
tors. Indeed, the expression of NEUROG3 can be detected as early as
day 6, when NKX6.1 protein is absent from all cells (Supplementary
Fig S1A and B). Consequentially, insulin-expressing cells that are
first detected 4 days after NEUROG3 induction (starting at day 10) do
not co-express NKX6.1 and are mostly polyhormonal (Fig 1F and G,
and Supplementary Fig S1C). In contrast, INS/NKX6.1 double-
positive beta-like cells can be readily detected only at later time
points (day 19, Fig 1G), suggesting that these cells differentiate from
PDX1/NKX6.1 double-positive progenitor cells. We thus hypothe-
sized that robust generation of PDX1+/NKX6.1+ progenitor cells
prior to induction of NEUROG3 would allow efficient generation of
beta-like cells in vitro. To determine which of the factors used
between days 6 and 8 in the original protocol (R, C, and N) are
responsible for the induction of PDX1, NKX6.1, and NEUROG3, we
incubated spheres with each of the factors alone or in different
combinations over days 6–8 (Fig 2A). Basal media with B27 but
lacking any additional factors served as the control condition. At the
end of day 8, each of these six conditions was further subdivided
into three different treatment groups: Media composition remained
the same as during days 6–8 (group 1) or changed either to EK
(group 2) or to EKN (group 3), resulting in 18 individual experimen-
tal conditions (Fig 2A). Spheres cultured under each condition were
analyzed at day 9.5 by flow cytometry to quantify the expression of
PDX1 and NKX6.1, and by conventional immunofluorescence analy-
sis for NKX6.1 and NEUROG3 expression. As shown in Fig 2B,
spheres within group 1 that had been exposed to retinoic acid
during days 6–8, either alone or in combination with other factors
(conditions 4, 5, and 6), exhibited highly efficient generation of
PDX1+ progenitors (> 88%), while the addition of C or N alone
(conditions 2 and 3) did not result in enhanced generation of PDX1+
cells over basal media alone. NKX6.1 was induced only weakly in
all group 1 conditions, with the exception of RC (condition 5),
which produced 45% PDX1/NKX6.1 double-positive cells. NKX6.1
expression was also strongly induced when cells were exposed to
retinoic acid alone or in combination with other factors followed by
treatment with EK (group 2) or EKN (group 3) (Fig 2B and C, condi-
tions 10–12 and 16–18). Endocrine differentiation, marked by
NEUROG3 expression, was noted only when spheres had been
exposed to N, either between days 5 and 9.5 (Fig 2C, conditions 3,
6, 9, and 12) or starting at the end of day 8 (Fig 2C, group 3, condi-
tions 13–18). Very few NEUROG3+ cells were detected in all other
conditions (Fig 2C, conditions 1, 2, 4, 5, 7, 8, 10, and 11). qPCR
analysis at day 8 of NEUROG3 and its downstream target NKX2.2
mRNA transcripts revealed significantly lower levels of these endo-
crine markers with R treatment when compared to the commonly
employed RCN condition (Supplementary Fig S1D). Notably, the
addition of vitamin C, recently shown to reduce endocrine differenti-
ation in hESCs (Rezania et al, 2014), did not significantly lower
NEUROG3 or NKX2.2 transcripts in our suspension culture system
during RCN or R treatment (Supplementary Fig S1D). Taken
together, these results indicate that R followed by EK treatment
leads to highly efficient generation of PDX1+/NKX6.1+ progenitors
(90%) and that the formation of bona fide NEUROG3-positive endo-
crine precursors is induced by treatment with N (Fig 2A–C, condi-
tion 10, green gates). Thus, by defining the temporal activities of
individual signaling factors alone and in combination, we can
induce transcription factor expression patterns characteristic of
different human embryonic pancreatic progenitor cells types
(PDX1+ and PDX1+/NKX6.1+ progenitors) without precocious
induction of endocrine differentiation.
Recapitulating human pancreas organogenesis to generate
endocrine progenitors
This improved and simplified differentiation protocol provides the
basis for subsequent efficient formation of insulin-producing cells in
suspension (Fig 3A). Endocrine differentiation in PDX1/NKX6.1
double-positive cells was induced by exposure to a cocktail of factors
consisting of TBP (T), ALK inhibitor (A), N, and K, (TANK) which
have previously been shown to activate NEUROG3 expression while
maintaining high expression of PDX1 and NKX6.1 (Nostro et al,
2011; Rezania et al, 2012) (Fig 3A and B). Importantly, while
NEUROG3 protein was undetectable before TANK treatment (Fig 3C,
day 9), cells exhibiting nuclear accumulation of NEUROG3 protein
appeared as early as 1 day following TANK treatment (Fig 3C, day
10). Thus, the expression of the pro-endocrine factor NEUROG3 is
rapidly induced through TANK treatment once PDX1+/NKX6.1+
progenitors are specified (Fig 3B, day 9). In contrast to the near-
uniform generation of PDX1+ and PDX1+/NKX6.1+ progenitor
populations following appropriate stimulation, endocrine differentia-
tion appears to be confined to a smaller population of cells. This
observation can be explained by the very short half-life of the
NEUROG3 protein (Roark et al, 2012), which allows only transient
detection of this marker in cells undergoing endocrine different-
iation. However, NEUROG3+ cells continued to be present when
clusters were exposed to the endocrine differentiation cocktail for
5 days (Fig 3C, day 14), indicating that endocrine cells were being
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generated throughout this period. To further characterize the
progenitors present in our cultures at the initiation of endocrine
differentiation, we analyzed the expression of NKX2.2, a down-
stream target of NEUROG3. NKX2.2 has recently been reported to
have distinct expression patterns during pancreatic organogenesis in
mouse and human (Jennings et al, 2013). While Nkx2.2 is readily
detectable in mouse pancreatic progenitor cells before Neurog3
expression, NKX2.2 protein is only observed after endocrine commit-
ment during human pancreas development. Similarly, we detected
NKX2.2 protein expression only after endocrine differentiation is
initiated at day 10, but not before in either PDX1+ or PDX1+/
NKX6.1+ progenitors (Fig 3C, data not shown). Of note, some
NKX2.2+ cells at day 10 co-express NEUROG3, and increasing
numbers of NKX2.2+/NEUROG3 cells are found at later time points
(Fig 3C). These data suggest that NKX2.2 could serve as a lineage
tracer for human cells that have undergone endocrine differentiation
induced by transient NEUROG3 expression. In summary, we have
established a novel differentiation strategy that faithfully recapitu-
lates human pancreas organogenesis and allows for the precise
control over the generation of PDX1+ and PDX1+/NKX6.1+ progenitors.
Efficient generation of PDX1+/NKX6.1+ pancreatic progenitor
cells prior to endocrine induction results in glucose-responsive
beta-like cells
To test the hypothesis that precocious activation of NEUROG3
expression results in immature polyhormonal cells and not INS/
NKX6.1 double-positive beta-like cells, we initiated endocrine differ-
entiation at day 7 in PDX1+ pancreatic progenitors by exposing
the cells to NEUROG3 inducers ALKi and Noggin (Supplementary
Fig S2A). While some single-hormone-positive cells were present at
day 13, many endocrine cells were double-positive for C-peptide
and glucagon (Supplementary Fig S2B). In further support of our
hypothesis, virtually all C-peptide-positive cells lacked expression of
A
C
B
Figure 2. Defining the temporal activities of individual signaling factors to efficiently generate PDX1+ and PDX1+/NKX6.1+ pancreatic progenitor populations
while preventing precocious induction of endocrine differentiation.
A–C Pancreatic progenitor marker expression at day 9.5 after treatment with conventional differentiation factors alone or in different combinations. Treatments
consisted of combinations of cyclopamine (C), Noggin (N), and retinoic acid (R) during days 6–8 followed by subdivision of each condition into three treatment
groups during day 9–9.5. Group 1: continuation of day 6–8 treatment; Group 2: treatment with EGF and KGF (EK); Group 3: treatment with EGF, KGF, and Noggin
(EKN). The condition selected for further studies (10) is marked with a green box. Data shown are representatives of results obtained in two independent
experiments. (A) Table detailing 18 different culture conditions that were evaluated. (B) Quantification of PDX1 (orange gate) and NKX6.1 (blue gate) protein-
expressing cells in individual conditions after 9.5 days of differentiation. (C) NKX6.1 and NEUROG3 protein expression assessed by whole-mount staining of
differentiated clusters at 9.5 days. Note robust NEUROG3 expression in all clusters exposed to N (conditions 3, 6, 9, and 12–18).
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NKX6.1 (Supplementary Fig S2C). To test whether correctly speci-
fied PDX1+/NKX6.1+ progenitor cells undergo differentiation
toward INS/NKX6.1 double-positive beta-like cells, we transferred
spheres differentiated using our new method into a basal media
without additional growth factors and monitored the establishment
of beta-like cells (Fig 4A). The percentage of GFP+ cells increased
from day 13 to day 19, reaching an average of 23  6% human C-
peptide-positive cells at days 19–21, likely reflecting continuous
generation of insulin-producing cells for ~4 days after removal of
NEUROG3-inducing factors (Fig 4B and C). Immunofluorescence
analysis of insulin-producing cells revealed co-expression and
nuclear localization of TFs critical for beta cell function (PDX1,
A
B
C
Figure 3. Recapitulating human pancreas organogenesis to generate endocrine progenitors.
A Schematic outlining a simplified differentiation strategy for the controlled, stepwise generation of pancreatic progenitor cell types.
B Time-course flow cytometric analysis illustrates the efficient generation of PDX1+ progenitor (orange gate) and PDX1+/NKX6.1+ progenitor (blue gate) populations.
Data from one of three independent experiments with similar results are shown.
C Immunofluorescence analysis of sections from differentiated clusters at indicated time points stained for human NKX2.2 (green) and NEUROG3 (red). Insets show
NEUROG3/NKX2.2 double-positive cells. Data from one of three independent experiments with similar results are shown.
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NKX6.1, and NKX2.2), but very few polyhormonal cells (Fig 4D).
Flow cytometry analysis of differentiated clusters showed a high
percentage of total cells (black gates) and C-peptide-positive beta-
like cells (green gates) co-staining for PDX1, NKX6.1, NXK2.2, ISL1,
PAX6, NEUROD1, and chromogranin A (CHGA) (Fig 4E). These
markers are normally found in both pancreatic progenitors and
mature beta cells. Quantification of C-peptide+ beta-like cells co-
staining for PDX1, NKX6.1, NKX2.2, ISL1, NEUROD1, PAX6, and
CHGA showed 84  7%, 75  20%, 92  5%, 86  5%,
95  4%, 93  5%, and 93  4% double-positive cells, respec-
tively (Fig 4F). Notably, only 3.2% of all differentiated cells co-
expressed C-peptide and the hormone glucagon (Fig 4E, red gate).
An important hallmark of mature human beta cells is their restricted
proliferative capacity. While 9.1  3.7% of C-peptide-negative cells
were actively proliferating, only 0.5  0.6% of C-peptide+ beta-like
cells co-stain for the proliferation marker Ki-67, indicating their
terminal differentiation state (Supplementary Fig S3A and B). Thus,
our optimized differentiation strategy results in the predominant
generation of post-mitotic, insulin-producing beta-like cells that co-
express critical beta cell markers.
To further characterize gene expression in beta-like cells at days
19–20, we took advantage of the GFP live marker to compare sorted
GFP+ beta-like cells and GFP populations to purified human islets.
hESC-derived beta-like cells showed high levels of insulin gene
transcripts, comparable to cadaveric islet preparations, while GFP-
negative populations exhibit only insignificant levels of the hormone
(Fig 5A). We also detected transcript levels for two other hormones
(GCG and SST) in GFP+ cells, likely due to contamination by the
small number of polyhormonal cells also expressing the GFP
reporter (Figs 5A and 4D and E). Consistent with the immunofluo-
rescence analysis (Fig 4D), transcripts for the TFs PDX1, NKX6.1,
and NKX2.2 normally found in both progenitor and mature beta
cells were expressed at comparable levels in GFP, GFP+, and
islet cells (Fig 5B). Transcripts for the mature human beta cell
transcription factors MAFA and MAFB were robustly expressed in
human islets and enriched in beta-like cells compared to GFP
populations. MAFB transcript levels in beta-like cells were similar to
human islets; MAFA expression levels were slightly lower (Fig 5B).
Other genes important for human beta cell functionality, including
the KATP channel components potassium inwardly rectifying
A E
B C
D F
C
Figure 4. Efficient generation of PDX1+/NKX6.1+ pancreatic progenitor cells prior to endocrine induction results in beta-like cells.
A Schematic outlining a simplified differentiation strategy for the controlled, stepwise generation of pancreatic progenitor and subsequent endocrine cell types. GFs,
growth factors.
B Micrographs of differentiated clusters at day 19 under light microscopy (left picture) or fluorescent microscopy showing prominent GFP expression (right picture; GFP
expression shown in white).
C Quantification of the percentage of human C-peptide-positive cells at day 19–21. Values are average  SD. n = 7 independent experiments.
D Immunofluorescence stainings of differentiated clusters at day 20 for insulin (INS), PDX1, NKX6.1, NKX2.2, and glucagon (GCG). One of four experiments with similar
outcome is shown.
E Representative flow cytometry plots depicting co-expression of pancreatic markers PDX1, NKX6.1, NKX2.2, ISL1, NEUROD1, PAX6, chromogranin A (CHGA), and GCG
with human C-peptide at indicated time points. Black gates mark percentage of total cells positive for indicated marker on y-axis. Green gates mark percentage of
double-positive beta-like cells. The red gate marks percentage of INS+/GCG+ bihormonal cells.
F Flow cytometric quantification of C-peptide-positive beta-like cells co-expressing markers in (E). A high percentage of beta-like cells co-express all genes usually
found in beta cells, but not the hormone GCG. Values are average  SD. n = 4 for PDX1, n = 19 for NKX6.1, n = 4 for NKX2.2, n = 9 for ISL1, n = 9 for NEUROD1,
n = 5 for PAX6, n = 6 for CHGA, and n = 5 for GCG. Analysis was performed at days 15–21 of differentiation.
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channel, subfamily J, member 11 (KIR6.2, also known as KCJN11)
and ATP-binding cassette, subfamily C, member 8 (SUR1, also
known as ABCC8), the glucose metabolism enzyme glucokinase
(GCK, also known as HK4), and the prohormone convertase 1/3
(PC1/3) necessary for insulin biosynthesis, were enriched in GFP-
positive beta-like cells at levels similar to or exceeding those found
in human islets (Fig 5C). In contrast, mRNA levels for the progeni-
tor marker SOX9 were reduced in beta-like cells compared to GFP
progenitors (Fig 5D). The somewhat higher SOX9 expression in
human islets is likely the result of contamination with SOX9-positive
duct cells. Thus, our gene expression analysis suggested that hESC-
derived beta-like cells possess the molecular machinery necessary
for beta cell function, including insulin biosynthesis and glucose
metabolism. Further investigations revealed that day 19 beta-like
cells contain 2.5  1.2 lg, 0.32  0.12 lg, and 310  143 ng
insulin, human C-peptide, and proinsulin per lg DNA, respectively
(Fig 5E). These values are comparable to ~2.8 lg insulin, ~0.55 lg
C-peptide, and ~150 ng proinsulin per lg DNA for human islets as
recently published (Rezania et al, 2014). Western blot analysis for
proinsulin and mature insulin further confirmed efficient insulin
protein processing in hESC-derived beta-like cells, reaching
59  2% of the extent of processing observed in purified human
islets (Supplementary Fig S4A and B). Ultrastructural analysis of
differentiated cell clusters by transmission electron microscopy
revealed that many cells contained secretory vesicles exhibiting
electron-dense cores or rod-like structures, akin to what is observed
in human beta cells (Fig 5F). To further investigate the functional
properties of in vitro differentiated beta-like cells, we performed
glucose-stimulated insulin secretion assays, in which we measured
the release of human C-peptide, a by-product of endogenous insulin
A
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E F G
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B
Figure 5. Beta-like cells exhibit key features of bona fide human beta cells and are glucose responsive.
A–D Quantitative PCR analysis of selected gene transcripts in sorted GFP+ beta-like cells (green bars), GFP populations (blue bars) and human islet preparations (black
bars). Results shown relative to the endogenous control GAPDH. RQ, relative quantification. Values are average  SD. n = 4 independent experiments for hESC-
derived cell populations at days 19–20 and n = 3 for human islets.
E Insulin, human C-peptide, and proinsulin content relative to DNA in beta-like cells at day 19. Data presented are average  standard error (n = three independent
experiments, technical duplicates).
F Transmission electron microscopy images of beta-like cells at day 20. One of three experiments with similar results is shown. Scale bar, 500 nm. Insets represent
secretory vesicles akin to granules present in bona fide human beta cells.
G Glucose-stimulated insulin secretion (GSIS) of human islets and beta-like cells at days 19–20. Y-axis indicates ratio of insulin secreted in low glucose conditions to
that secreted in high glucose conditions. Values are average  standard deviation (SD). n = 3 for human islets and n = 10 for beta-like cells.
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biosynthesis secreted in an equimolar ratio to insulin. hESC-derived
beta-like cells analyzed at days 19–21 responded to an increase in
glucose concentration from 2.8 mM to 16.7 mM by secreting
1.8  0.9 fold more C-peptide, a response similar to the 1.9  0.6-
fold increase detected with human islets (Fig 5G). Thus, beta-like
cells generated by our optimized differentiation strategy express crit-
ical beta cell genes, synthesize high levels of mature insulin, exhibit
ultrastructural features of bona fide beta cells, and secrete endoge-
nous insulin in response to changes in physiological concentrations
of glucose.
hESC-derived beta-like cells remain glucose responsive after
short-term transplantation
To determine whether hESC-derived beta-like cells can maintain
their glucose responsiveness in vivo, we transplanted approximately
5 million cells under the kidney capsule of immunodeficient mice
(days 19–21 spheres consisting of progenitors and beta-like cells).
Mice transplanted with 4,000 human islets served as controls. Seven
to 10 days post-surgery, human C-peptide levels were measured in
overnight fasted mice, before and after the administration of a
glucose bolus. As expected, mice that received human islet grafts
exhibited low levels of insulin secretion upon fasting, followed by a
marked increase in circulating insulin after glucose challenge (aver-
age of 221  116 pM, Fig 6A). Similar to mice carrying human
islets, fasted mice transplanted with hESC-derived beta-like cells
had low levels of circulating C-peptide. Upon glucose administra-
tion, C-peptide concentrations in sera of these mice also increased,
albeit at lower levels than in mice transplanted with human islets
(average of 40  28 pM, Fig 6A). This lower number might be
explained in part by the different numbers of cells transplanted
in the human islet and beta-like cell groups. Indeed, each human
islet contains on average 1,000 cells, of which 50% are beta cells
(Cabrera et al, 2006). Thus, 4,000 human islets contain approxi-
mately 2.0 × 106 bona fide beta cells. Since hESC-differentiated
spheres contain on average 23% beta-like cells, only about
1.15 × 106 beta-like cells were transplanted per mouse. Normaliza-
tion based on beta cell number indicates that hESC-derived beta-like
cells secreted 70  48 pM human C-peptide per 2.0 × 106 cells,
representing approximately one-third of the insulin secreted from
each human cadaveric beta cell (Fig 6A). Hematoxylin and eosin
staining, together with immunofluorescence analysis of the hESC
grafts at 2 weeks post-transplantation, demonstrated prominent
islet-like structures positive for human C-peptide (Fig 6B and C).
Beta-like cells also maintained co-expression of the key beta cell TFs
PDX1, NKX6.1, and NKX2.2, and only few cells co-expressed other
hormones such as glucagon and somatostatin (Fig 6C). To further
investigate the functional properties of hESC-derived beta-like cells
in vivo, we transplanted clusters under the kidney capsule of mice
rendered diabetic through treatment with the beta cell toxin strepto-
zotocin. Mice that received grafts exhibit significantly reduced blood
glucose (BG) levels at all time points analyzed when compared to
control animals (Fig 6D). While BG levels were significantly
reduced in graft-bearing mice, they continued to exhibit hyperglyce-
mic BG values over time. This is likely due to the limited number of
beta-like cells that can be transplanted under the kidney capsule in
one mouse. It has previously been shown that 4,000 human islets
are required to establish long-term euglycemia in diabetic mice.
Transplantation of a smaller number of human islets (1,500 islets)
reduces blood glucose levels only for 7 days post-transplantation,
after which hyperglycemia returned (Fiaschi-Taesch et al, 2010).
Our surgical procedure permits the transplantation of ~1.15 × 106
beta-like cells, substantially less than the ~2.0 × 106 beta cells pres-
ent in the 4,000 human islets previously found to be required for the
long-term reversal of diabetes. Hence, the observed reduction in BG
levels, but lack of complete diabetes reversal in mice bearing hESC-
derived transplants, is not unexpected given this technical
constraint. Taken together, our in vivo data demonstrate that hESC-
derived beta-like cells maintain their differentiated phenotype and
remain glucose responsive after a short engraftment period in vivo
and highlight their potential therapeutic value.
Discussion
Herein, we describe a simplified differentiation protocol replicating
key steps of embryonic pancreas organogenesis for the defined
generation of human pancreatic progenitor and endocrine cell types
from hESCs that results in the formation of glucose-responsive beta-
like cells in vitro. hESC-derived beta-like cells exhibit key features of
cadaveric human beta cells both in vitro and in vivo, most notably
their ability to respond to physiological increases in glucose concen-
trations by secreting insulin. Gene expression analysis of beta-like
cells indicates the presence of factors essential for beta cell function,
proper biosynthesis of mature insulin, glucose metabolism, and
insulin secretion at levels comparable to human islets. In addition,
beta-like cells display ultrastructural features of bona fide human
beta cells, such as appropriate secretory vesicles. Thus, critical
elements necessary for the generation and appropriate processing,
packaging, and storing of insulin in its bioactive mature form are
present in these hESC-derived cells. Finally, beta-like cells remained
functional after short-term transplantation and reduced blood
glucose levels in a murine model of diabetes, further confirming the
correct differentiation state of the cells.
Recently, two other groups have reported the derivation of
glucose-responsive beta-like cells from hESCs that share many char-
acteristics of the beta-like cells described here (Pagliuca et al, 2014;
Rezania et al, 2014). However, both studies focused on optimizing
the later stages of direct differentiation, while employing parts of
published protocols, namely the addition of RCN, to establish
pancreatic progenitor populations. Our data demonstrate that the
generation of pancreatic progenitors using this method also results
in the undesirable generation of immature polyhormonal endocrine
cells that lack expression of the critical beta cell transcription factor
NKX6.1. Indeed, both published studies do note appreciable popula-
tions of C-peptide/insulin-positive cells that lack NKX6.1 expres-
sion. We demonstrate that polyhormonal cells result from
precocious endocrine induction in PDX1+ pancreatic progenitors
(lacking NKX6.1 expression), which can be avoided by omitting
BMP inhibitors during the pancreas specification stage. Further, our
detailed analysis of the effects of individual RCN factors on the
expression of key pancreatic markers revealed that retinoic acid
alone is sufficient to induce proficient generation of more than 98%
PDX1+ pancreatic progenitors. Subsequent exposure to EGF and
KGF results in the rapid and effective activation of NKX6.1 in these
cells, generating PDX1+/NKX6.1+ progenitor cells with the ability to
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give rise to beta-like cells in vitro. These simplified differentiation
conditions enable the efficient generation of human pancreatic and
more restricted endocrine progenitor populations from pluripotent
stem cells without unwanted formation of polyhormonal cells. Thus,
we conclude that this simplified differentiation protocol more
closely resembles key aspects of early human pancreas development
and, as such, represents an improvement over published protocols.
Although the mechanisms of endocrine differentiation in vivo are
not completely understood, previous studies in rodents have shown
an important role for Notch signaling. While initially required for
the generation of competent progenitor cells, a subsequent reduc-
tion of Notch signaling is necessary for the induction of Neurog3
expression that initiates endocrine differentiation (Shih et al, 2012).
In the context of in vitro differentiation, previous studies have
shown that direct inhibition of Notch signaling by gamma secretase
inhibitors or the use of BMP and TGFb/ALK inhibitors results in
increased insulin expression at later stages (Mfopou et al, 2010;
Nostro et al, 2011; Pagliuca et al, 2014; Rezania et al, 2014). We
employed BMP and ALK inhibition over a 5-day window to induce
NEUROG3 expression specifically in PDX1+/NKX6.1+ progenitors,
which resulted in the efficient generation of INS+/NKX6.1+ beta-
like cells, while only few polyhormonal cells were observed (~3%).
Likely these unwanted cells originate from the small percentage of
PDX1 pancreatic progenitors present at the time of endocrine induc-
tion. In contrast to the formation of PDX1+ and PDX1+/NKX6.1+
progenitors that occurs rapidly (36–48 h after the addition of induc-
ing factor(s) and uniformly in the majority of cells, endocrine differ-
entiation occurs over a prolonged period and is confined to a small
A
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Figure 6. Beta-like cells remain glucose responsive after short-term transplantation.
A Levels of circulating human C-peptide measured in sera of mice 7–10 days after transplantation with either 4,000 human islets or 5.0 × 106 direct differentiated cells
(containing approximately 1.15× 106 beta-like cells). Fasting and challenge sera were collected following an overnight fast and 1 h after intraperitoneal glucose
challenge, respectively. Dashed line separates raw data from serum C-peptide measurements normalized to the number of beta cells present in each human islet
graft (4,000 human islets transplanted each containing ~1,000 cells, approximately 50% of which are beta cells, hence 2.0× 106 beta cells present in grafts total).
n = 5 for human islets and n = 12 for hESC-derived grafts.
B Hematoxylin and eosin staining of day 14 graft. k, kidney; g, graft. Representative data from one of three mice are shown.
C Immunofluorescence staining of differentiated hESC grafts 2 weeks post-transplantation for human C-peptide, glucagon (GCG), somatostatin (SST), PDX1, NKX6.1, and
NKX2.2. Representative data from one of three mice are shown.
D Blood glucose (BG) levels of mice treated with streptozotocin to ablate endogenous beta cells (STZ) followed by transplantation (Tx) of beta-like cell containing
clusters either at day 0 or at day 4 as indicated (n = 8, two independent differentiation experiments). Values are average  SD. Statistical significance was calculated
using two-tailed t-test. *P < 0.05, **P < 0.01, and ***P < 0.001. Control (CTRL) group: 6–9 animals.
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subset of total cells. This might be a reflection of the situation
observed during normal human pancreas development where only
few progenitor cells initiate the endocrine differentiation program at
any given time (Jennings et al, 2013). While simultaneous wide-
spread induction of endocrine differentiation in a majority of
PDX1+/NKX6.1+ progenitor population would greatly reduce differ-
entiation time and increase beta-like cell yield, our results point to a
regulation of NEUROG3 expression that requires subtle, yet tempo-
rally precise adjustment that appears more complex than just Notch
inhibition. As our differentiation protocol allows for a tight control
of NEUROG3 expression, it could be used in future studies to iden-
tify novel regulators of NEUROG3 gene expression, and ideally to
achieve uniform NEUROG3 activation during direct differentiation
in vitro.
While cadaveric islet preparations are widely accepted as the
gold standard for studying human beta cells, several problems asso-
ciated with their use remain. For example, their performance and
utility depend on a number of confounding factors: genetic variance,
age and life style of the donor, isolation time, islet purity, and ship-
ping conditions. By eliminating the constraints of availability and
reproducibility, we anticipate that hESC-derived beta-like cells will
provide an important tool in accelerating a more complete under-
standing of the biology of human beta cells.
Taken together, our fast and simplified protocol provides precise
temporal control over the generation of subsequent pancreatic
progenitor and endocrine cell types and results in the establishment
of human beta-like cells that exhibit glucose responsiveness in vitro
and in vivo. Our suspension-based direct differentiation approach is
scalable, and our ability to produce large numbers of beta-like cells
will further accelerate efforts in delivering a safe and efficient cell
therapy to patients suffering from diabetes. Furthermore, through the
production and maintenance of different developmental cell popula-
tions, our approach can be used for more detailed investigations into
human pancreas development and human beta cell function that
were previously impossible due to limited donor material, such as
large-scale drug screens and genomewide gene function studies.
Material and Methods
Cell culture
Undifferentiated MEL1 INSGFP/W reporter cells (Micallef et al, 2012)
were maintained on mouse embryo fibroblast feeder layers (Milli-
pore) in hESC media as described (Guo et al, 2013b). Suspension-
based differentiations were carried out as follows. Briefly, confluent
cultures were dissociated into single-cell suspension by incubation
with TrypLE (Gibco). Cells were counted and each well of 6-well
low-adherence plates were seeded with 5.5 × 106 cells in 5.5 ml
hESC media supplemented with 10 ng/ml activin A (R&D Systems)
and 10 ng/ml heregulin-b1 (Peprotech). Plates were placed on an
orbital shaker at 100 rpm to induce sphere formation as described
(Schulz et al, 2012). To induce definitive endoderm differentiation,
aggregates were collected 24 h later in a 50-ml falcon tube, allowed
to settle by gravity, washed once with PBS, and re-suspended in d1
media [RPMI (Gibco) containing 0.2% FBS, 1:5,000 ITS (Gibco),
100 ng/ml activin A, and 50 ng/ml WNT3a (R&D Systems)].
Clusters from three wells were combined into two wells at this point
and distributed into fresh low attachment plates in 5.5 ml d1 media.
Media thereafter were changed daily, by removing either 4.5 ml
media (at the end of d1) or 5.5 ml media the following days and
adding back 5.5 ml fresh media until day 9. After day 9, only 5 ml
of media was removed and added daily. Differentiation employing
published protocols has been described (Rezania et al, 2012; Schulz
et al, 2012). Media in our simplified differentiation protocol consist
of the following: d2: RPMI containing 0.2% FBS, 1:2,000 ITS, and
100 ng/ml activin A; d3: RPMI containing 0.2% FBS, 1:1,000 ITS,
2.5 lM TGFbi IV (CalBioChem), and 25 ng/ml KGF (R&D Systems);
d4-5: RPMI containing 0.4% FBS, 1:1,000 ITS, and 25 ng/ml KGF;
d6-7: DMEM (Gibco) with 25 mM glucose containing 1:100 B27
(Gibco), 3 nM TTNBP (Sigma); d8: DMEM with 25 mM glucose
containing 1:100 B27, 3 nM TTNBP, and 50 ng/ml EGF (R&D
Systems); d9: DMEM with 25 mM glucose containing 1:100 B27,
50 ng/ml EGF, and 50 ng/ml KGF; d10-14: DMEM with 25 mM
glucose containing 1:100 B27, 500 nM LDN-193189 (Stemgent),
30 nM TBP (Millipore), 1,000 nM ALKi II (Axxora), and 25 ng/ml
KGF; and d15-21: DMEM with 2.8 mM glucose containing 1:100
Glutamax (Gibco) and 1:100 NEAA (Gibco). Human islets were from
Prodo Laboratories or the UCSF Islets and Cellular Production Facility.
Mice
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice (NSG) were obtained from
Jackson Laboratories. Mice used in this study were maintained
according to protocols approved by the University of California, San
Francisco Committee on Laboratory Animal Resource Center. For
kidney capsule grafts, approximately 5.0 × 106 hESC-differentiated
cells in spheres and 4,000 human islet equivalents were trans-
planted as described (Szot et al, 2007; Russ & Efrat, 2011). For
glucose-induced insulin secretion, mice were fasted overnight and
serum was collected before and after intraperitoneal administration
of 3 g/kg D-glucose solution. For induction of diabetes, mice were
administered 35 mg/kg streptozotocin via intraperitoneal injection
for 5 days. Graft-bearing kidneys were removed for immunofluoresce-
nce analysis. No statistical method was employed to determine sample
size, mice were not randomized, and analysis was not blinded.
Cell sorting and flow cytometric analysis
Briefly, spheres were collected and allowed to settle by gravity.
Clusters were washed once in PBS and dissociated by gentle
pipetting after 12- to 15-min incubation in Accumax (innovative cell
technologies). For sorting, cell suspension were filtered and re-
suspended in FACS buffer consisting of PBS (UCSF cell culture
facility) containing 2 mM EDTA (Ambion) and 1% BSA (Sigma).
Dead cells were excluded by DAPI (Sigma) staining. Cell sorting was
performed on a FACSAria II (BD Bioscience). For flow-based analy-
sis, dissociated cells were fixed with 4% paraformaldehyde (Elec-
tron Microscopy Science) for 15 min at room temperature, followed
by two washes in PBS. Samples were either stored at 4C or immedi-
ately stained with directly conjugated antibodies. Data analysis was
performed with FlowJo software. Mouse glucagon and mouse
human C-peptide antibodies were conjugated in-house by the UCSF
Antibody Core and/or with Antibody Labeling Kits (Molecular
Probes) according to manufacturer’s instructions. Commercially
available directly conjugated antibodies are listed below:
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Antibody Manufacturer
Human PAX6–Alexa647 BD Bioscience
Islet-1–PE BD Bioscience
NKX6.1–Alexa647 BD Bioscience
NKX6.1-PE BD Bioscience
Chromogranin A–PE BD Bioscience
NeuroD1–Alexa647 BD Bioscience
PDX1-PE BD Bioscience
Ki-67–Alexa647 BD Bioscience
Electron microscopic analysis
Spheres were fixed by adding 37C warm 0.1 M sodium cacodylate
solution (Sigma) containing 2% paraformaldehyde (Electron Micro-
scopy Science) and 2.5% glutaraldehyde (Electron Microscopy
Science), 3 lM CaCl2 (Sigma), final pH 7.4. Spheres were then trans-
ferred to 4C for approximately 18 h, followed by standard process-
ing and analysis by the Electron Microscope Lab/Diabetes Center
Microscope Core.
Immunofluorescence analysis
Spheres were fixed for 15–30 min at room temperature with 4%
paraformaldehyde, followed by multiple washes in PBS. Whole-
mount staining was performed in suspension, by first blocking
overnight at 4C in blocking buffer consisting of CAS-block (Invi-
trogen) with 0.2% Triton X-100 (Fisher). Primary antibodies were
incubated overnight at 4C in blocking buffer, followed by washes
in PBS containing 0.1% Tween-20 (PBS-T, Sigma) and incubation
in appropriate secondary antibodies diluted in PBS-T overnight at
4C. The next day, clusters were washed in PBS-T followed by PBS
and mounted with Vectashield (Vector) on glass slides. For
sectioning of clusters, spheres were embedded in 2% agar (Sigma),
followed by dehydration, paraffin embedding, and sectioning. Cut
sections were rehydrated and treated with and antigen retrieval
solution (Biogenex) before incubation in primary antibodies over-
night at 4C in blocking buffer. The next day, sections were
washed three times in PBS-T and incubated with appropriate
secondary antibodies for 30–40 min at room temperature in PBS-T.
Appropriate Alexa-conjugated secondary antibodies were
purchased from JAX or Molecular Probes and used at 1:500 dilu-
tions. Slides were washed in PBS-T and PBS before mounting in
Vectashield. Nuclei were visualized with DAPI. Images were
acquired using a Leica SP5 microscope or a Zeiss ApoTome.
Primary antibodies were employed as follows:
Antigen Species Dilution Manufacturer
Human C-peptide Mouse 1:200 Chemicon
Human C-peptide Rat 1:1,000 DSHB
Insulin Mouse 1:1,000 Sigma
Insulin Guinea pig 1:500 DAKO
Glucagon Mouse 1:1,000 Sigma
NKX6.1 Mouse 1:100 DSHB
Antigen Species Dilution Manufacturer
NKX2.2 Mouse 1:20 DSHB
PDX1 Goat 1:200 R&D Systems
Human NEUROG3 Sheep 1:300 R&D Systems
Ki-67 Rabbit 1:100 NovoCastra
qPCR analysis
Total RNA was isolated with TRIzol (Sigma) or micro/mini
RNeasy kit (Qiagen) and reverse-transcribed using the iScript
cDNA Kit (Bio-Rad) according to manufacturer’s instructions.
qPCR analysis was performed on an ABI 7900 HT Fast Real-Time
PCR System (Applied Biosystems) and CFX Connect Real-Time
System (Bio-Rad) using standard protocols. Primers were TaqMan
probes (Applied Biosystems) and/or as published previously (Liu
et al, 2014). P-values were calculated using a two-tailed Student’s
t-test.
Content analysis
Insulin, human C-peptide, and proinsulin analyses were performed
by measuring an aliquot of acidic ethanol lysed clusters with
commercially available ELISA kits (insulin cat. 80-INSMR-CH10,
human C-peptide cat. 80-CPTHU-CH01, and proinsulin cat.
80-PINHUT-CH01; all from Alpco). Total DNA was quantified by
PicoGreen (Invitrogen) assay and normalized to the percentage of
C-peptide-positive cells in each sample.
Western blotting for proinsulin/insulin
Cell lysates were resolved on 4–12% acrylamide gradient SDS–PAGE
gels (NuPAGE, Invitrogen) normalized to cellular DNA (Quant-iT
dsDNA, Molecular Probes). The samples were then electrotrans-
ferred to nitrocellulose membranes and immunoblotted with guinea
pig anti-insulin, which recognizes both proinsulin and insulin, as
previously described (Haataja et al, 2013). Immunoblotting with
anti-tubulin was used as a confirmatory loading control. HRP-
conjugated secondary antibodies (Jackson ImmunoResearch) were
used for enhanced chemiluminescence detection (Millipore). The
analysis was performed four times with isolated human islets used
as a positive control.
Glucose-stimulated insulin secretion
Human islets or hESC-derived spheres were transferred into tubes
and washed twice with Krebs–Ringer Bicarbonate buffer (KRB)
containing 2.8 mM glucose. Samples were incubated for one hour in
2.8 mM glucose containing KRB to allow equilibration of cells.
2.8 mM buffer was removed and replaced with fresh KRB contain-
ing 2.8 mM glucose for one hour followed by incubation for another
hour in KRB containing 16.7 mM glucose. After the incubation
period, buffers were collected for human C-peptide-specific ELISA
analysis using a commercially available kit (Alpco).
Supplementary information for this article is available online:
http://emboj.embopress.org
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